Check out part 2 in our 3-part series on how to optimize PMA outcomes for combinations while working within the current environmental constraints!
To work within the “status quo” environment that oncology combination therapies face in regards to market access, Walter Colasante, Ashley Fraser, and Owen Male of Charles River Associates examine the right questions and decisions companies must ask during clinical development:
Nano Medicine l Nano Drug Delivery l Bio-Nanotech l Precision Medicine l Personalised Medicine I Machine Learning l
9moVery pertinent insights Ashley et al